Caliper Expects Further $10M-$25M in Divestitures; Eyes IVIS, LabChip Growth

The firm's CEO told investors at the JP Morgan Healthcare Conference that divestitures would be time-phased, with new revenues replacing those lost when businesses or product lines are shed.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.